<DOC>
	<DOC>NCT01323478</DOC>
	<brief_summary>To evaluate the long-term safety and tolerability of flexible doses, 15 and 20 mg/day, of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD)</brief_summary>
	<brief_title>Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>Patients who completed 8week shortterm treatment study, 13267A (NCT01140906), for Major Depressive Episode immediately prior to enrolment in this extension study Any current psychiatric disorder other than MDD as defined in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSMIV TR) Female patients of childbearing potential who are not using effective contraception Use of any psychoactive medication The patient, in the investigator's clinical judgment, has a significant risk of suicide. Other protocoldefined inclusion and exclusion criteria applied.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Depressive Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Depressive Disorder, Major</keyword>
	<keyword>Mood Disorders</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Behavioural Symptoms</keyword>
</DOC>